Bonus BioGroup
Press Room

Press Releases 2022

Press Releases 2022

In a preclinical trial carried out in the US, success was demonstrated in treating Cytokine Release Syndrome affecting approximately 41%-78% of cancer patients treated with immunotherapies using Bonus BioGroup's drug product MesenCure

Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products.

Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products.

FOR MORE INVESTOR RELATION INFORMATION

Press Release, Announcements publication and more

Bonus BioGroup

Image

 

Terms of UsePrivacy Policy | Login        

© 2022 Bonus BioGroup Ltd. All Rights Reserved. Designed By Netron Israel Ltd.